CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

April 24, 2024

https://www.prnewswire.com/news-releases/csl-vifor-and-travere-therapeutics-announce-european-commission-approves-filspari-sparsentan-for-the-treatment-of-iga-nephropathy-302125154.html

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
/PRNewswire/ — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the European Commission has granted conditional marketing…
https://www.prnewswire.com/news-releases/csl-vifor-and-travere-therapeutics-announce-european-commission-approves-filspari-sparsentan-for-the-treatment-of-iga-nephropathy-302125154.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.